
Current Price | $0.83 | Mkt Cap | $83.6M |
---|---|---|---|
Open | $0.80 | P/E Ratio | -0.66 |
Prev. Close | $0.83 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.78 - $0.83 | Volume | 284,853 |
52-Wk Range | $0.53 - $2.34 | Avg. Daily Vol. | 228,168 |
Current Price | $0.83 | Mkt Cap | $83.6M |
---|---|---|---|
Open | $0.80 | P/E Ratio | -0.66 |
Prev. Close | $0.83 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.78 - $0.83 | Volume | 284,853 |
52-Wk Range | $0.53 - $2.34 | Avg. Daily Vol. | 228,168 |
The best Bull and Bear pitches based on recency and number of recommendations.
Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMDGlobeNewswire•September 19, 2018ADVM-022 is a unique single-administration gene therapy delivered intravitreally for the treatment of wAMDOPTIC… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about ADVM.
Recs
Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD
GlobeNewswire•September 19, 2018
ADVM-022 is a unique single-administration gene therapy delivered intravitreally for the treatment of wAMD
OPTIC Phase 1 clinical trial initiation expected in 4Q18
MENLO PARK, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ADVM-022. ADVM-022 is a novel gene therapy candidate for the treatment of wet age-related macular degeneration (wAMD).
“The FDA’s Fast Track designation is an important recognition of our ADVM-022 gene therapy program,” said Leone Patterson, interim president and chief executive officer of Adverum Biotechnologies. “We look forward to working with the FDA and benefiting from the potential expedited development and regulatory path offered by their Fast Track program.”
A Fast Track designation is intended to facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill unmet medical needs. The designation enables more frequent communication with the FDA throughout a product candidate’s development and review process. The designation also provides eligibility for Priority Review and Accelerated Approval, which may potentially result in a shorter FDA review process.
Recs
ready to take off
Recs
nev
Find the members with the highest scoring picks in ADVM.
cvdynasty0 (98.70) Score: +183.78
The Score Leader is the player with the highest score across all their picks in ADVM.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
zzlangerhans | 98.77 | 11/9/2018 |
![]() |
1Y | $3.74 | -78.26% | +65.38% | +143.64 | 0 Comment | |
SnPee500 | 71.78 | 8/18/2021 |
![]() |
5Y | $2.28 | -64.34% | +3.61% | +67.95 | 0 Comment | |
mistermiranga | 99.84 | 7/11/2022 |
![]() |
5Y | $1.53 | -46.86% | +18.98% | -65.84 | 0 Comment | |
Hobooda | < 20 | 5/24/2021 |
![]() |
5Y | $3.54 | -77.03% | +10.01% | -87.04 | 0 Comment | |
axnxg | 70.42 | 1/8/2021 |
![]() |
5Y | $12.16 | -93.31% | +20.63% | -113.94 | 0 Comment | |
Dananator2 | < 20 | 12/21/2020 |
![]() |
5Y | $12.15 | -93.31% | +25.79% | -119.10 | 0 Comment | |
fredj123 | 31.05 | 11/23/2020 |
![]() |
3W | $12.49 | -93.49% | +28.50% | -121.99 | 0 Comment | |
usubanas | 96.96 | 7/8/2020 |
![]() |
5Y | $21.65 | -96.24% | +46.17% | -142.42 | 0 Comment | |
portefeuille | 97.96 | 4/29/2019 |
![]() |
5Y | $6.65 | -87.77% | +56.41% | -144.19 | 0 Comment | |
Bigsef77 | 47.15 |
|
![]() |
3Y | $3.25 | -74.98% | +71.00% | -145.98 | 2 Comments |
See what the Wall Street professionals think, according to their public statements and filings.